STOCK TITAN

Prestige Consmr Healthcare Inc - PBH STOCK NEWS

Welcome to our dedicated page for Prestige Consmr Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consmr Healthcare stock.

Prestige Consumer Healthcare Inc (NYSE: PBH) maintains leadership in over-the-counter healthcare through trusted brands like Clear Eyes and Summer’s Eve. This news hub provides investors and industry professionals with essential updates on corporate developments, regulatory milestones, and market strategies.

Access comprehensive coverage of PBH’s operational updates including earnings announcements, product innovations, and supply chain initiatives. Our curated news collection offers context for understanding the company’s position in competitive OTC markets across North America and international regions.

Key updates feature strategic partnerships, quality assurance developments, and responses to evolving consumer health trends. The resource serves as a centralized reference for tracking PBH’s commitment to product stewardship and operational efficiency in dynamic healthcare markets.

Bookmark this page for streamlined access to press releases and analysis on PBH’s market navigation. Regular updates ensure stakeholders maintain current awareness of corporate initiatives impacting long-term value creation in consumer healthcare.

Rhea-AI Summary

Prestige Consumer Healthcare (NYSE:PBH) will release its fiscal 2022 third quarter earnings on February 3, 2022, prior to market opening. A conference call is scheduled for the same day at 8:30 a.m. ET to discuss the results. U.S. and Canadian participants can dial 844-233-9440 or 574-990-1016 internationally, using conference ID 4798187. An internet webcast will be available, with a replay accessible from the Investor Relations page. Prestige markets a variety of consumer healthcare products including Monistat, BC, and Dramamine across several international markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
-
Rhea-AI Summary

Prestige Consumer Healthcare reported record revenue of $276.2 million for Q2 2022, a 16.3% increase from the previous year and 10.5% organic growth. The diluted EPS rose to $0.89, while adjusted EPS hit $1.02, reflecting a 30.8% year-over-year growth. Net operating cash flow was $61.2 million with adjusted free cash flow at $61.9 million. The company raised its full-year revenue and EPS guidance, anticipating total revenue between $1,050 million and $1,060 million while projecting adjusted EPS between $3.93 and $3.98.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
-
Rhea-AI Summary

Prestige Consumer Healthcare Inc. (NYSE:PBH) will release its fiscal 2022 second quarter earnings on November 4, 2021, before market opening. A conference call to discuss the results is scheduled for the same morning at 8:30 a.m. ET, with dial-in options available for U.S. and international participants. An archived replay will be accessible on the company's Investor Relations page. Prestige Consumer Healthcare markets a diverse range of health products across North America and internationally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
Rhea-AI Summary

Prestige Consumer Healthcare (NYSE:PBH) reported Q1 fiscal 2022 revenue of $269.2 million, marking a 17.3% increase from the previous year. Diluted EPS rose 32.5% to $1.14. Operating cash flow reached $69.3 million, while free cash flow was $67.8 million. The company raised its full-year outlook, projecting revenue of $1.045 billion or more and adjusted EPS of $3.90 or more, driven by solid brand performance and the recent acquisition of TheraTears, anticipated to add $40 million in revenue and $0.07 in EPS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags
-
Rhea-AI Summary

Prestige Consumer Healthcare Inc. (NYSE:PBH) has finalized its acquisition of TheraTears and other consumer brands from Akorn Operating Company for $230 million in cash. The asset purchase is expected to enhance Prestige's eye care portfolio, bringing approximately $60 million in annual revenue and contributing $20 million in EBITDA. The transaction is valued at under 10x pro-forma EBITDA, providing anticipated tax benefits of ~$30 million. The acquisition was financed through available cash, an Asset Based Loan, and refinancing of its term loan maturing in 2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
-
Rhea-AI Summary

Prestige Consumer Healthcare (NYSE:PBH) announced a $230 million cash acquisition of a portfolio from Akorn Operating Company, including the TheraTears brand. This acquisition is projected to generate approximately $60 million in annual revenue and $20 million in EBITDA. The transaction, expected to close in fiscal Q2, offers tax benefits of about $30 million and is valued at less than 10x pro-forma EBITDA. The TheraTears brand, a leader in the dry eye segment, aligns with Prestige's growth strategy and operational model.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
Rhea-AI Summary

Prestige Consumer Healthcare (PBH) reported strong fiscal 2021 results, exceeding guidance with revenue of $943.4 million and record diluted earnings per share (EPS) of $3.25. In Q4, revenues were $237.8 million, down 5.4% year-over-year, while net income was $35.5 million. The company generated $213.4 million in adjusted free cash flow and provided a positive outlook for fiscal 2022, forecasting revenues of $957 to $962 million and adjusted EPS of $3.58 or more.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.22%
Tags
-
Rhea-AI Summary

Prestige Consumer Healthcare (NYSE:PBH) will release its fiscal 2021 fourth quarter and year-end earnings on May 6, 2021, before market opens. A conference call will follow at 8:30 a.m. ET to discuss the results. Participants can join via phone or listen to a webcast on the Investor Relations page of the company’s website. Telephonic replays will be available for a week post-call. Prestige markets various consumer healthcare products across North America and internationally, with well-known brands like Monistat®, Summer’s Eve®, and Dramamine®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
-
Rhea-AI Summary

Prestige Consumer Healthcare Inc. (NYSE: PBH) has priced an upsized offering of $600 million in 3.750% senior notes due 2031, to be completed by March 1, 2021. The proceeds will be used to redeem all outstanding 6.375% senior notes due 2024. The offering is being made only to qualified institutional buyers under Rule 144A of the Securities Act. Prestige Consumer Healthcare markets a diverse range of consumer healthcare products across various countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
Rhea-AI Summary

Prestige Consumer Healthcare Inc. (NYSE: PBH) announced a private offering of up to $500 million in new senior notes due 2031 through its subsidiary, Prestige Brands, Inc. The funds will be utilized to redeem $600 million of outstanding 6.375% Senior Notes due 2024 and cover related expenses. The redemption is contingent upon the completion of the new notes offering. These notes will be offered only to qualified institutional buyers under Rule 144A and Regulation S of the Securities Act, and it does not constitute an offer to sell or solicit an offer to buy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
none
Prestige Consmr Healthcare Inc

NYSE:PBH

PBH Rankings

PBH Stock Data

4.07B
48.86M
1.3%
109.04%
3.07%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
TARRYTOWN